Nomura maintained a buy rating on Torrent Pharma but raised the target to Rs 2199 from Rs 1838 earlier. The potential acquisition of Cipla will be a big deal and it makes strategic sense. The acquisition will require large debt and equity dilution.
Nomura maintained a buy rating on Torrent Pharma but raised the target to Rs 2199 from Rs 1838 earlier. The potential acquisition of Cipla will be a big deal and it makes strategic sense. The acquisition will require large debt and equity dilution.